This protocol establishes orthotopic cancer models by implanting tumor cells directly into their organ of origin in mice or rats, creating physiologically relevant tumor microenvironments for preclinical research. The method evaluates therapeutic interventions under conditions that closely mimic human cancer progression, providing reliable safety and efficacy data essential for translational drug development. By the end of the procedure, you should be able to establish functional orthotopic tumor models in rodents suitable for longitudinal therapeutic assessment and biomarker validation studies.
What are Orthotopic Cancer Models?
Orthotopic cancer models serve as gold standard preclinical tools for evaluating cancer therapeutics by establishing tumors in their anatomically correct organ locations within mice or rats. These models preserve the natural tumor microenvironment, including organ-specific vasculature, immune cell interactions, and stromal components that influence therapeutic response (Zitvogel et al., 2016). The approach enables accurate assessment of drug efficacy, toxicity profiles, and metastatic potential by maintaining physiological conditions that subcutaneous models cannot replicate. Researchers assess readiness by confirming access to appropriate cell lines, surgical expertise, proper animal facilities, and longitudinal monitoring capabilities for comprehensive therapeutic evaluation.
Prerequisites
- Advanced knowledge of sterile surgical techniques and rodent survival surgery
- Understanding of cancer biology and tumor progression mechanisms
- Familiarity with cell culture maintenance and preparation protocols
- Access to appropriate mouse or rat strains and surgical facilities
- Institutional Animal Care and Use Committee (IACUC) approval
Objectives
- Establish anatomically relevant tumor models in rodents for therapeutic testing
- Preserve natural tumor microenvironment and organ-specific interactions
- Enable accurate safety and efficacy assessment of cancer therapeutics
- Generate translatable preclinical data for clinical development
- Evaluate metastatic potential and progression patterns in living animals
Animals
Immunocompromised mice (NOD/SCID or nude mice, 6-8 weeks old, 20-25g) for human cell lines, or immunocompetent mice (C57BL/6, BALB/c, 6-8 weeks old, 20-25g) for syngeneic models. Rats (Sprague-Dawley or Wistar, 8-10 weeks old, 200-250g) for larger organ access requiring greater surgical space. Animals should be obtained from certified vendors and acclimated for minimum 7 days before procedures in appropriate housing conditions.
Duration:
04:30:00 per mouse, 05:15:00 per rat (assumes 45-60 minute surgical procedure with 2-hour pre-operative preparation, 30-45 minute recovery monitoring, and 45-minute cleanup). For multiple animals: add 75-90 minutes per additional animal for surgery and recovery.
Estimated Cost
$15,850 USD for new equipment setup, plus $200-500 per animal depending on strain and species (immunocompromised mice $200-250, immunocompetent mice $50-75, rats $300-500). Anesthesia system represents major cost component at $10,000 new or $6,000 used. Additional costs include housing, veterinary care, and monitoring equipment.
Supplies
- Sterile surgical instruments for rodent surgery (scalpels, forceps, scissors)
- Microsurgical needle holders and suture materials (6-0 or 7-0)
- Cell suspension preparation materials
- Sterile syringes and needles (25-30 gauge for mice, 22-25 gauge for rats)
- Rodent anesthesia delivery system and monitoring equipment
- Heating pads and rectal temperature probes for rodents
- Sterile surgical drapes and gauze appropriate for small animals
- Antiseptic solutions (betadine, alcohol)
- Post-operative analgesics approved for rodents
- Tumor cell lines validated for orthotopic implantation in rodents
Tools
- Surgical microscope or magnification system for rodent procedures
- Rodent anesthesia machine with appropriate vaporizers
- Pulse oximeter designed for mice and rats
- Cell counter for accurate cell enumeration
- Centrifuge for cell preparation
- Sterile biosafety cabinet for cell handling
- Surgical lighting system with adjustable intensity for small animals
Materials
Cancer cell lines, culture media, phosphate buffered saline, anesthetic agents (isoflurane), analgesic medications (buprenorphine, meloxicam), suture materials, laboratory mice or rats, identification tags
Protocol
Step 1: Prepare Cell Suspension
Harvest tumor cells during logarithmic growth phase and prepare single-cell suspension at predetermined concentration (typically 1×10^5 to 1×10^6 cells for mice, 1×10^6 to 5×10^6 cells for rats). Wash cells three times with sterile phosphate buffered saline to remove culture media and debris. Count cells using hemocytometer or automated cell counter to ensure accurate dosing for rodent implantation. Verify cell viability exceeds 95% using trypan blue exclusion method. Keep cell suspension on ice throughout procedure to maintain viability and prevent clumping during rodent surgery.
Step 2: Prepare Surgical Environment
Establish sterile surgical field using appropriate draping techniques and antiseptic preparation protocols suitable for rodent surgery. Set up surgical microscope with adequate magnification (10-40x) for precise visualization of mouse or rat organs. Prepare all surgical instruments through autoclave sterilization and arrange in sterile instrument tray designed for small animal procedures. Verify rodent anesthesia machine functionality and prepare isoflurane concentrations appropriate for mouse (1-3%) or rat (2-4%) anesthesia. Ensure heating pad maintains rodent body temperature at 37°C throughout procedure to prevent hypothermia in small animals.
Step 3: Anesthetize and Position Rodent
Induce anesthesia using isoflurane (3-4% for induction, 1.5-2.5% for maintenance in mice; 4-5% induction, 2-3% maintenance in rats) and monitor vital signs continuously throughout procedure. Position mouse in dorsal recumbency for abdominal organs or lateral position for thoracic procedures, using appropriate restraints designed for small animals. Secure positioning using soft restraints to prevent movement while maintaining respiratory function in the anesthetized rodent. Apply ophthalmic ointment to prevent corneal drying during prolonged anesthesia in mice or rats. Verify adequate anesthetic depth through toe pinch reflex and respiratory rate monitoring (60-220 breaths/minute for mice, 70-115 for rats) before beginning surgical procedure.
Step 4: Access Target Organ in Rodent
Make appropriate surgical incision (typically 1-2cm in mice, 2-3cm in rats) to access target organ while minimizing trauma to surrounding tissues and maintaining sterile technique throughout the procedure. Use blunt dissection techniques to identify and isolate target organ from adjacent structures in the mouse or rat anatomy. Position organ for optimal visualization and access to injection site while preserving vascular supply and innervation specific to rodent physiology. Apply gentle retraction using moistened gauze to maintain tissue hydration without causing mechanical damage to delicate rodent tissues. Identify optimal injection site that avoids major blood vessels and provides adequate tissue depth for cell implantation in the small animal model.
Step 5: Inject Tumor Cells into Rodent Organ
Load predetermined cell suspension volume (typically 10-20 microliters for mice, 20-50 microliters for rats) into sterile syringe with appropriate gauge needle (27-30 gauge for mice, 25-27 gauge for rats). Insert needle into target organ parenchyma at shallow angle to prevent penetration through opposing surface in the small rodent organ. Inject cell suspension slowly over 30-60 seconds to prevent tissue disruption and cell leakage from delicate rodent tissues. Maintain needle position for additional 30 seconds after injection to allow tissue sealing around injection site in the mouse or rat organ. Apply gentle pressure with sterile gauze for 60 seconds to achieve hemostasis and prevent cell spillage into the rodent peritoneal cavity.
Step 6: Close Surgical Site in Rodent
Inspect injection site for bleeding or cell leakage and achieve appropriate hemostasis using gentle pressure or electrocautery appropriate for small animal surgery. Return organ to anatomical position within the mouse or rat body cavity and verify normal positioning and color indicating adequate blood supply. Close body wall in layers using appropriate suture materials (6-0 or 7-0 absorbable sutures for internal layers, 5-0 or 6-0 non-absorbable for skin closure in rodents). Apply sterile wound dressing if indicated and ensure secure closure to prevent dehiscence or infection in the small animal. Document surgical procedure details including cell number, injection volume, rodent identification, and any complications encountered during implantation.
Step 7: Post-Operative Monitoring of Rodent
Transfer mouse or rat to recovery area with controlled temperature (22-24°C) and continuous monitoring capabilities for immediate post-operative period. Monitor vital signs including respiratory rate (60-220/min mice, 70-115/min rats), heart rate, and body temperature every 15 minutes until rodent fully recovers from anesthesia. Administer appropriate analgesic medications (buprenorphine 0.05-0.1 mg/kg or meloxicam 1-5 mg/kg) according to established pain management protocols for mice and rats. Provide supportive care including subcutaneous fluids if indicated and monitor for signs of surgical complications in the small animal. Document recovery progress and establish monitoring schedule for tumor growth assessment and rodent welfare evaluation.
Analyze the Results
Tumor Growth Assessment in Rodents
Monitor tumor development in mice or rats using appropriate imaging modalities (ultrasound, MRI, or bioluminescence) beginning 7-14 days post-implantation depending on expected growth kinetics in the rodent model. Measure tumor dimensions using digital calipers and calculate tumor volume using ellipsoid formula (length x width x height x 0.52) appropriate for small animal measurements. Document growth curves by plotting tumor volume against time to determine doubling time and growth patterns specific to the rodent strain used. Establish endpoint criteria based on tumor size (typically 10% body weight in mice, 5% in rats), animal welfare indicators, and experimental objectives. Use statistical analysis (linear regression, ANOVA) to compare growth rates between treatment groups in the rodent cohorts.
Therapeutic Efficacy Evaluation in Animal Models
Begin therapeutic interventions once tumors reach predetermined size (typically 50-100 mm³ in mice, 100-200 mm³ in rats) to ensure adequate tumor establishment while maintaining treatment window in the rodent model. Monitor tumor response through serial imaging and measurement protocols established during growth assessment phase for the specific animal species. Calculate percent tumor growth inhibition compared to vehicle-treated control mice or rats using standardized formulas. Assess survival endpoints and time-to-progression measures for comprehensive efficacy evaluation in the rodent cohorts. Document treatment-related toxicity through body weight monitoring, clinical observations, and hematological assessments when indicated for mouse and rat safety assessment.
Troubleshooting
Poor Tumor Take Rate in Rodents
This may indicate inadequate cell viability, inappropriate cell concentration for the rodent model, or technical factors affecting implantation success in mice or rats. Verify cell viability exceeds 95% before implantation and optimize cell concentration through dose-response studies specific to the animal strain used. Ensure rapid implantation following cell preparation to prevent viability loss and maintain cells on ice throughout the rodent surgical procedure. Consider using extracellular matrix components or growth factors to enhance cell engraftment in challenging organ locations within mouse or rat anatomy. Evaluate injection technique to ensure adequate tissue penetration without cell leakage from small rodent organs.
Excessive Surgical Morbidity in Animal Models
This may reflect inadequate anesthetic protocols for rodents, surgical trauma inappropriate for small animals, or post-operative complications affecting mouse or rat welfare and experimental validity. Optimize anesthetic protocols through consultation with veterinary staff experienced in rodent anesthesia and implement appropriate pain management strategies for mice and rats. Refine surgical technique to minimize tissue trauma and reduce operative time through practice with rodent anatomy and training in small animal surgery. Enhance post-operative monitoring and supportive care protocols to identify and address complications early in the mouse or rat recovery period. Consider alternative injection approaches or cell delivery methods for organs with challenging surgical access in small animal models.
Inconsistent Tumor Growth Across Rodent Cohorts
This may indicate variability in cell preparation, injection technique, or host factors affecting tumor establishment and progression in mice or rats. Standardize cell culture conditions and passage protocols to ensure consistent cell populations across rodent experiments. Implement quality control measures for cell counting and viability assessment to reduce dosing variability in mouse and rat implantations. Use randomization strategies for animal assignment and treatment allocation to minimize systematic biases within rodent cohorts. Consider host factors including age, strain, and immune status that might influence tumor growth patterns differently in mice versus rats.
Unexpected Metastatic Patterns in Animal Models
This may reflect cell line characteristics, injection technique, or host factors influencing metastatic dissemination patterns specific to mouse or rat physiology. Document metastatic sites through comprehensive necropsy examination and histopathological assessment to characterize dissemination patterns in the rodent model. Compare observed metastatic patterns with published literature for specific cell lines in mice and rats. Consider technical factors including injection pressure and cell spillage that might create artificial metastatic deposits in the small animal cavity. Evaluate whether observed patterns align with human disease progression for translational relevance from the rodent model.
Safety and Efficacy Assessment in Rodent Models
Establish comprehensive safety monitoring protocols including regular clinical observations, body weight measurements, and behavioral assessments throughout the experimental period for mice and rats. Implement standardized scoring systems for pain assessment in rodents and establish humane endpoint criteria to ensure animal welfare while maximizing data collection opportunities from the mouse or rat cohorts. Monitor treatment-related toxicity through hematological analysis, organ function tests, and histopathological examination of target and off-target tissues when indicated in the rodent models.
Design efficacy assessment protocols that incorporate multiple endpoints including tumor growth inhibition, survival analysis, and biomarker evaluation to provide comprehensive therapeutic evaluation in mice or rats. Use appropriate statistical methods for survival analysis including Kaplan-Meier curves and log-rank tests for group comparisons within rodent cohorts. Calculate therapeutic indices comparing efficacious doses with toxic doses to assess therapeutic windows relevant for clinical translation from the animal model. Document dose-response relationships and identify optimal dosing regimens for subsequent studies in the rodent system.
Model Validation and Characterization
Validate orthotopic rodent models through comprehensive characterization including histopathological analysis, biomarker expression profiling, and comparison with human disease characteristics. Assess tumor microenvironment composition including immune cell infiltration, vascular architecture, and stromal components to ensure physiological relevance of the mouse or rat model. Document growth kinetics, metastatic patterns, and therapeutic responsiveness to establish model reliability and reproducibility across experimental conditions in rodent cohorts.
Compare orthotopic rodent model characteristics with corresponding subcutaneous models to demonstrate advantages in therapeutic assessment and translational relevance from mice and rats. Establish standard operating procedures for model generation, monitoring, and endpoint assessment to ensure consistency across research groups and experimental conditions using the same animal strains. Create detailed protocols for tissue collection and analysis to maximize data yield from each experimental mouse or rat while maintaining scientific rigor and animal welfare standards.
This methodology represents current best practices established through collaborative research at leading cancer research institutions, validated across multiple tumor types in mice and rats, and refined through continuous development in translational oncology laboratories worldwide since the 1990s.
Key Takeaways
- Orthotopic cancer models in mice and rats provide physiologically relevant tumor microenvironments essential for accurate preclinical therapeutic assessment.
- Proper surgical technique and post-operative monitoring in rodents prevent complications that compromise model validity and ensure reliable data.
- Experts recommend orthotopic rodent models as superior to subcutaneous approaches for evaluating cancer therapeutics and predicting outcomes.
Related Articles
- Subcutaneous Tumor Models for Cancer Research – Alternative tumor modeling approach using subcutaneous implantation in mice and rats for rapid screening and preliminary assessment.
- Patient-Derived Xenograft Models Protocol – Advanced cancer modeling using human tumor tissue implantation in immunocompromised mice to preserve patient-specific characteristics.
- Tumor Imaging and Monitoring Techniques – Comprehensive guide for non-invasive tumor assessment using ultrasound, MRI, and bioluminescence imaging in rodent models.
